Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #SLE or #SSc. These relapses were significant. Switching to BCMA-CAR or BCMA-TCE restored response. Should BCMA instead of CD19 be targeted initially?@RheumNow https://t.co/lgdsJQm3xY
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression.
